A Pilot Double-blind, Placebo-controlled Crossover Study to Explore the Possible Benefit of AUT00063, an Oral Modulator of Voltage-gated Potassium Channels, in Adult Post-lingual Unilateral Cochlear Implant Recipients: The QuicK+fire-study
Phase of Trial: Phase II
Latest Information Update: 29 May 2017
At a glance
- Drugs AUT 00063 (Primary)
- Indications Hearing loss
- Focus Therapeutic Use
- Acronyms The QuicK+fire-study
- Sponsors Autifony Therapeutics
- 23 May 2017 Status changed from active, no longer recruiting to completed.
- 13 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2016 New trial record